Myelodysplastic syndromes: diagnosis and treatment
DP Steensma - Mayo Clinic Proceedings, 2015 - Elsevier
In the past few years, new biological insights into the myelodysplastic syndromes (MDS)
resulting from molecular genetic analysis have improved pathologic understanding, but …
resulting from molecular genetic analysis have improved pathologic understanding, but …
Hypomethylating agent combination strategies in myelodysplastic syndromes: hopes and shortcomings
B Ball, A Zeidan, SD Gore, T Prebet - Leukemia & lymphoma, 2017 - Taylor & Francis
The hypomethylating agents (HMA) azacitidine and decitabine are both approved by the
FDA for the treatment of myelodysplastic syndromes (MDS). Although heralded as a …
FDA for the treatment of myelodysplastic syndromes (MDS). Although heralded as a …
Lenalidomide with or without erythropoietin in transfusion-dependent erythropoiesis-stimulating agent-refractory lower-risk MDS without 5q deletion
A Toma, O Kosmider, S Chevret, J Delaunay… - Leukemia, 2016 - nature.com
After failure of erythropoiesis-stimulating agents (ESAs), lenalidomide (LEN) yields red
blood cell (RBC) transfusion independence (TI) in 20–30% of lower-risk non-del5q …
blood cell (RBC) transfusion independence (TI) in 20–30% of lower-risk non-del5q …
Ezatiostat hydrochloride for the treatment of myelodysplastic syndromes
D Mahadevan, GR Sutton - Expert Opinion on Investigational …, 2015 - Taylor & Francis
Introduction: Myelodysplastic syndromes (MDSs) are associated with significant morbidity
due to ineffective hematopoiesis. Given the limited number of drugs approved by the FDA …
due to ineffective hematopoiesis. Given the limited number of drugs approved by the FDA …
[HTML][HTML] Recent advances in the 5q-syndrome
A Pellagatti, J Boultwood - Mediterranean journal of hematology …, 2015 - ncbi.nlm.nih.gov
The 5q-syndrome is the most distinct of the myelodysplastic syndromes (MDS) and patients
with this disorder have a deletion of chromosome 5q [del (5q)] as the sole karyotypic …
with this disorder have a deletion of chromosome 5q [del (5q)] as the sole karyotypic …
Expanding role of lenalidomide in hematologic malignancies
N Ghosh, MR Grunwald, O Fasan… - Cancer Management …, 2015 - Taylor & Francis
Lenalidomide is an immunomodulatory agent that has been approved by the US Food and
Drug Administration for treatment of multiple myeloma, deletion 5q myelodysplastic …
Drug Administration for treatment of multiple myeloma, deletion 5q myelodysplastic …
CSNK1A1 mutations and gene expression analysis in myelodysplastic syndromes with del(5q)
E Bello, A Pellagatti, J Shaw, C Mecucci… - British journal of …, 2015 - Wiley Online Library
Mutations of CSNK1A1, a gene mapping to the commonly deleted region of the 5q‐
syndrome, have been recently described in patients with del (5q) myelodysplastic …
syndrome, have been recently described in patients with del (5q) myelodysplastic …
Myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms: an update on risk stratification, molecular genetics, and therapeutic approaches …
Myelodysplastic syndromes are a heterogeneous group of clonal hematopoietic stem cell
disorders characterized by ineffective hematopoiesis, peripheral cytopenias, and a variable …
disorders characterized by ineffective hematopoiesis, peripheral cytopenias, and a variable …
CSNK1A1 mutations and isolated del (5q) abnormality in myelodysplastic syndrome: a retrospective mutational analysis
AE Smith, AG Kulasekararaj, J Jiang, S Mian… - The Lancet …, 2015 - thelancet.com
Background A mechanism for clonal growth advantage in isolated del (5q) disease remains
elusive. CSNK1A1 resides on the critically deleted region, and deletion of this gene has …
elusive. CSNK1A1 resides on the critically deleted region, and deletion of this gene has …
Genome sequencing in myelodysplastic syndromes: can molecular mutations predict benefit from hypomethylating agent therapy?
EJ Lee, AM Zeidan - Expert Review of Hematology, 2015 - Taylor & Francis
Evaluation of: Bejar R, Lord A, Stevenson K, et al. TET2 mutations predict response to
hypomethylating agents in myelodysplastic syndrome patients. Blood 2014 Oct 23; 124 (17) …
hypomethylating agents in myelodysplastic syndrome patients. Blood 2014 Oct 23; 124 (17) …